Recent work demonstrates that GLS inhibitors (e.g., CB-839) reduce glutamine metabolism, depriving tumor cells of key intermediates (glutamate, α-ketoglutarate) required for anabolic growth and redox balance (151). Here, GLS is linked to neoplasm.